AGENDA

Uniform Formulary Beneficiary Advisory Panel (UF BAP)
For February 2025, May 2025 and Addendum to May 2025 (held July 10, 2025) Department of War Pharmacy and Therapeutics Committee Meetings
June 22, 2026 at 10:15 AM Eastern Daylight Time

Day #1 Meeting

The UF BAP meetings occurring on June 22-24, 2026, will include information presented at the DoW Pharmacy and Therapeutics (P&T) Committee meetings from February 2025, May 2025, Addendum to May 2025 held July 10, 2025, August 2025, November 2025, Addendum to November 2025 held January 16, 2026, February 2026 and May 2026. The information presented on June 22 (Day #1) will include the recommendations from the February 2025 (presented in the morning) and May 2025 and the July 10 Addendum (presented in the afternoon) P&T meetings. The information presented on June 23 (Day #2) will include the recommendations from August 2025 (presented in the morning) and November 2025, Addendum to November 2025 held January 16,2026 and February 2026 (presented in the afternoon) P&T meetings. The information presented on June 24(Day #3) will include the information presented at the May 2026 P&T meeting.

Administrative Meeting 9:00 AM - 10:00 AM Eastern Daylight Time

<u>Information from the February 2025 DoW P&T Meeting</u>

- **General session starts at 10:15 AM Eastern Daylight Time**
- **Roll Call**
- **Therapeutic Class Reviews**

  Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effectiveness analyses along with the DoW P&T Committee recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.

  The DoW P&T Committee made recommendations for the following drugs/drug classes during the February 2025 meeting.

  - **Drug Class Reviews**
    - *Sleep Disorders Class: Wakefulness Promoting Agents Subclass*
    - *Narcotic Analgesics and Combinations Class: Buprenorphine and Combinations Subclass*
  - **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
    - *acoramidis (Attruby)—Miscellaneous Neurological Agents for Transthyretin Amyloidosis*
    - *arimoclomol (Miplyffa)—Miscellaneous Neurological Agents for Niemann-Pick*

Disease

- *aripiprazole oral film (Opipza)—Atypical Antipsychotic Agents*
- *crinecerfont (Crenessity)—Miscellaneous Endocrine Agents for Congenital Adrenal Hyperplasia*
- *filgrastim-txid (Nypozi)—White Blood Cell Stimulants: Filgrastims*
- *imatinib oral solution (Imkeldi)—Oncological Agents: Chronic Myeloid Leukemia*
- *inavolisib (Itovebi)—Oncological Agents: Breast Cancer*
- *marstacimab-hncq (Hympavzi)—Antihemophilic Factors*
- *minocycline 40 mg extended-release capsules (Emrosi)—Antibiotics: Tetracyclines*
- *nilotinib tartrate tablets (Danziten)—Oncological Agents: Chronic Myeloid Leukemia*
- *olezarsen (Tryngolza)—Antilipidemic-2 Agents for familial chylomicronemia syndrome*
- *Omnipod Intro G6/Libre 2 Plus pods and kits automated insulin delivery system: Insulins: Miscellaneous Insulin Devices*
- *revumenib (Revuforj)—Oncological Agents for Acute Leukemia*
- *ustekinumab-aaub (Wezlana)—Targeted Immunomodulatory Biologics (TIBs): Interleukin-23 (IL-23) inhibitors*
- *vanzacaftor/tezacaftor/deutivacaftor (Alyftrek)—Cystic Fibrosis Agents*

➢ **Utilization Management Issues**

- **PA Criteria—Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
  - *Narcotic Analgesics and Combinations: tramadol 75 mg tablets*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
  - *Atopy Agents—dupilumab (Dupixent)*
  - *Oncological Agents—asciminib (Scemblix)*
  - *Psoriasis Agents—tapinarof 1% cream (Vtama)*
  - *TIBs: Miscellaneous Interleukins—nemolizumab (Nemluvio)*
  - *TIBs: IL-17 inhibitors—bimekizumab (Bimzelx)*
  - *Weight Loss Agents—tirzepatide (Zepbound)*
- **PA Criteria—Updated PA Criteria for Reasons Other Than New Indications**
  - *Antidepressants and Non-Opioid Pain Syndrome Agents: Selective*

Serotonin Reuptake Inhibitors—vortioxetine (Trintellix)

- *Attention Deficit Hyperactivity Disorder Agents: Stimulants—lisdexamfetamine (Vyvanse)*
- *Atopy Agents: Oral Janus Kinase-1 (JAK-1) Inhibitors—abrocitinib (Cibinqo) and upadacitinib (Rinvoq)*
- *Miscellaneous Neurological Agents: Niemann-Pick Disease—levacetylleucine (Aqneursa)*
- *Miscellaneous Neurological Agents: Transthyretin amyloidosis—tafamidis (Vyndaqel), tafamidis meglumine (Vyndamax) and eplontersen (Wainua)*
- *Oncological Agents—encorafenib (Braftovi)*
- *Ophthalmic: Dry Eye Agents—cyclosporine 0.05% ophthalmic emulsion unit dose (Restasis, generic unit dose)*
- *TIBs: Tumor necrosis factor (TNF) inhibitors—etanercept (Enbrel)*
- *TIBs: Miscellaneous—baricitinib (Olumiant), deucravacitinib (Sotyktu) and tofacitinib (Xeljanz)*
- *TIBs: Updates for Inflammatory Bowel Disease*
  - *ustekinumab (Stelara)*
  - *guselkumab (Tremfya)*
  - *risankizumab on-body injector (Skyrizi OBI)*
  - *mirikizumab (Omvoh)*
  - *vedolizumab (Entyvio*
  - *infliximab (Zymfentra)*

- **Removal of PA Criteria**
  - *Migraine Agents: Triptans—frovatriptan and naratriptan; return of frovatriptan to UF status*
  - *Gastrointestinal-2 Agents for Constipation-Predominant Irritable Bowel Syndrome—linaclotide (Linzess) and lubriprostone (Amitiza)*

➢ **Panel Discussions**

The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoW P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.

➢ **Break for Lunch 12:45 PM – 1:45 PM Eastern Daylight Time**

Information from the May 2025 DoW P&T Meeting

- **General session starts at 1:45 PM Eastern Daylight Time**
- **Roll Call**
- **Therapeutic Class Reviews**

  Members of the DHA POD FMB will present relative clinical and cost-effectiveness analyses along with the DoW P&T Committee recommendations for the UF and any recommended complete exclusion candidates.

  The DoW P&T Committee made recommendations for the following drugs/drug classes during the May 2025 meeting.

  - **Drug Class Reviews**
    - *Targeted Immunomodulatory Biologics (TIBs): Interleukin (IL)-1, IL-6 and Cytotoxic T-Lymphocyte Associated Antigen-4 Immunoglobulin (CTLA4-Ig) Subclasses*
    - *Breast Cancer Agents: Cyclin-Dependent Kinase (CDK) Inhibitors Subclass*
  - **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
    - *benzgalantamine (Zunveyl) – Alzheimer's Agents*
    - *concizumab-mtci (Alhemo) – Antihemophilic Agents*
    - *diazoxide choline (Vykat XR) – Miscellaneous Metabolic Agent for hyperphagia in Prader-Willi Syndrome*
    - *hydrochlorothiazide 10 mg/mL powder for oral suspension (Inzirqo) – Diuretic Agents*
    - *hydroxyurea 100 mg/mL oral solution (Xromi) – Oncological Agent for Sickle Cell Anemia*
    - *letermovir extended release (ER) pellets (Prevymis) – Antiviral for cytomegalovirus (CMV) infection*
    - *mirdametinib (Gomekli) – Oncological Agent for neurofibromatosis*
    - *suzetrigine (Journavx) – Pain Agents*
    - *trazodone 10 mg/mL oral solution (Raldesy) – Antidepressants and Non-Opioid Pain Syndrome Agents: Serotonin Antagonist and Reuptake Inhibitor*
    - *ustekinumab-auuz (Otulfi) – Targeted Immunomodulatory Biologics (TIBs): Interleukin-23 (IL-23) inhibitors; biosimilar for Stelara*
    - *ustekinumab-stab (Steqeyma) – TIBs IL-23s; biosimilar for Stelara*
    - *ustekinumab-ttwe (Pyzchiva) – TIBs IL-23s; biosimilar for Stelara*
    - *ustekinumab-kfce (Yesintek) – TIBs IL-23s; biosimilar for Stelara*

- *ustekinumab-aekn (Selardsi) – TIBs IL-23s; biosimilar for Stelara*
- *vimseltinib (Romvimza) – Oncological Agent for tenosynovial giant cell tumor*

➢ **Utilization Management Issues**

- **PA Criteria—New Manual PA Criteria**
  - *Anti-infectives: Anthelmintics—mebendazole (Emverm)*
  - *Endocrine Agents Miscellaneous: Antihyperglycemic-Glucocorticoid Receptor Blocker—mifepristone (Korlym)*
  - *Leukotriene Modifying Agents—zileuton (Zyflo), zileuton ER generic*
- **PA Criteria—Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
  - *Diabetes Non-Insulin: Biguanides—metformin 750 mg IR tablet*
  - *Narcotic Analgesics and Combinations—tramadol 100 mg immediate release (IR) tablet*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
  - *Miscellaneous Metabolic Agents: setmelanotide (Imcivree)*
  - *Miscellaneous Immunological Agents: Oral Agents—house dust mite allergen extract (Odactra)*
  - *TIBs: IL-23s—guselkumab (Tremfya)*
  - *Leukemia and Lymphoma Agents: BTK Inhibitors—acalabrutinib (Calquence)*
  - *Oncological Agents: Lung Cancer—sotorasib (Lumakras)*
  - *Diabetes Non-Insulin: Glucagon-Like Peptide 1-ReceptorAgonits—semaglutide (Ozempic)*
- **PA Criteria—Updated PA Criteria for Reasons other than New FDA-Approved Indications**
  - *Corticosteroids-Immune Modulators: Atopic Dermatitis—crisaborole (Eucrisa)*
  - *Antigout Agents—febuxostat (Uloric)*
  - *Oncological Agents*
    - *fedratinib (Inrebic)*
    - *selumetinib (Koselugo)*
    - *pomalidomide (Pomalyst)*
    - *ripretinib (Qinlock*
    - *midostaurin (Rydapt)*
    - *capmatinib (Tabrecta)*

- *tepotinib (Tepmetko)*
- *pexidartinib (Turalio)*
- *quizartinib (Vanflyta)*
- *larotrectinib (Vitrakvi)*
- *dacomitinib (Vizimpro)*
- *gilteritinib (Xospata)*

▪ *Miscellaneous Metabolic Agents*

- *odevixibat (Bylvay)*
- *maralixibat (Livmarli)*

▪ *Antipsychotic Agents for Parkinson's Psychosis—pimavanserin (Nuplazid)*

- **Removal of PA Criteria**
  - *Multiple Sclerosis Agents: Methyl Fumarate—dimethyl fumarate (Tecfidera)*
  - *Alzheimer's Agents—memantine ER (Namenda XR)*
- **Brand Over Generic Authorization and Tier 1 Copay**
  - *Renin-Angiotensin Antihypertensives: Combinations: sacubitril/valsartan (Entresto)*
- **Weight Loss Drugs PA Criteria: Comprehensive Lifestyle Intervention**

➢ **<u>Information from the Addendum to the May 2025 DoW P&T Meeting held on July 10, 2025</u>**

- **Prior Authorizations: Targeted Immunomodulatory Biologics (TIBs): Interleukin (IL-23) Inhibitors Prior Authorization Criteria and Implementation Plan**
  - *The DoW P&T Committee held a virtual meeting on July 10, 2025 as an addendum to the May 2025 P&T Committee meeting, to update the PA criteria and implementation plan for the IL-23 Inhibitors.*

➢ **Panel Discussions**

The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoW P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.

➢ **Adjournment**